Literature DB >> 26578321

Presentation and Outcomes After Surgery for Primary Hyperparathyroidism During an 18-Year Period.

Mark Thier1, Erik Nordenström2, Anders Bergenfelz2, Martin Almquist2.   

Abstract

PURPOSE: The objective of this study is to analyze whether the trend towards operating on patients with less severe primary hyperparathyroidism (pHPT) than earlier is reflected in a change of preoperative presentation and surgical outcome.
METHODS: In this longitudinal cohort study, patients with pHPT subjected to first time surgery were compared in three time periods: 1989-1994, 1995-2000, and 2001-2006 in this longitudinal cohort study.
RESULTS: There were 404 patients. Median levels of preoperative ionized calcium were lower in 2001-2006 compared to 1989-1994; 1.45 versus 1.50 versus 1.45 mmol/L; p < 0.001. Preoperative parathyroid hormone levels in patients with parathyroid adenoma were lower in 2001-2006 than in 1989-1994; 10.0 versus 11.6 pmol/L; p 0.04. Median preoperative bone mineral density, BMD, in the whole cohort did not differ between time periods. Median pre- and postoperative glomeruli filtration rate, GFR, and 25-hydroxy-vitamin D3 remained unchanged between period 1 and period 3. Adenoma weight was lower in 2001-2006 than 1989-1994; 0.70 versus 0.50 g; p 0.04. Cure rate did not change during observation time. There was no evidence for differences in change of BMD (femoral neck) after surgery between period 2 and 3 1995-2000 and 2001-2006, 0.798 versus 0.795 g/cm(2); p 0.67. GFR did not change significantly between 1989-1994 and 2001-2006, 74 versus 77 mL/min; p 0.43.
CONCLUSIONS: A significant change towards operating patients with smaller adenomas and lower preoperative calcium levels was evident throughout the observation period, but this did not correlate with differences in preoperative renal or skeletal function. We found no evidence for a change of postoperative renal function or skeletal function during observation time.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26578321     DOI: 10.1007/s00268-015-3329-5

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  30 in total

1.  Serum vitamin D metabolite concentrations in primary hyperparathyroidism.

Authors:  M T Nikkilä; J J Saaristo
Journal:  Ann Med       Date:  1989-08       Impact factor: 4.709

2.  Changing biochemical presentation of primary hyperparathyroidism.

Authors:  Martin Almquist; Anders Bergenfelz; Hans Mårtensson; Mark Thier; Erik Nordenström
Journal:  Langenbecks Arch Surg       Date:  2010-07-10       Impact factor: 3.445

Review 3.  The skeleton in primary hyperparathyroidism: a review focusing on bone remodeling, structure, mass, and fracture.

Authors:  P Christiansen
Journal:  APMIS Suppl       Date:  2001

Review 4.  Natural history of primary hyperparathyroidism.

Authors:  S J Silverberg
Journal:  Endocrinol Metab Clin North Am       Date:  2000-09       Impact factor: 4.741

5.  The Weight of the Resected Gland Predicts Rate of Success After Image-Guided Focused Parathyroidectomy.

Authors:  Olov Norlén; Anthony Glover; Nisar Zaidi; Adam Aniss; Mark Sywak; Stan Sidhu; Leigh Delbridge
Journal:  World J Surg       Date:  2015-08       Impact factor: 3.352

6.  Patients with primary hyperparathyroidism operated on over a 24-year period: temporal trends of clinical and laboratory findings.

Authors:  M Palmér; S Ljunghall; G Akerström; H O Adami; R Bergström; L Grimelius; C Rudberg; H Johansson
Journal:  J Chronic Dis       Date:  1987

7.  Justified follow-up: a final intraoperative parathyroid hormone (ioPTH) Over 40 pg/mL is associated with an increased risk of persistence and recurrence in primary hyperparathyroidism.

Authors:  Mohammad H Rajaei; Alex M Bentz; David F Schneider; Rebecca S Sippel; Herbert Chen; Sarah C Oltmann
Journal:  Ann Surg Oncol       Date:  2014-09-06       Impact factor: 5.344

8.  Glomerular filtration rate and parathyroid hormone secretion in primary hyperparathyroidism.

Authors:  F Tassone; L Gianotti; I Emmolo; M Ghio; G Borretta
Journal:  J Clin Endocrinol Metab       Date:  2009-10-06       Impact factor: 5.958

9.  BMD improvements after operation for primary hyperparathyroidism.

Authors:  Lars Rolighed; Peter Vestergaard; Lene Heickendorff; Tanja Sikjaer; Lars Rejnmark; Leif Mosekilde; Peer Christiansen
Journal:  Langenbecks Arch Surg       Date:  2012-11-07       Impact factor: 3.445

Review 10.  Surgical strategy for sporadic primary hyperparathyroidism an evidence-based approach to surgical strategy, patient selection, surgical access, and reoperations.

Authors:  Radu Mihai; Marcin Barczynski; Maurizio Iacobone; Antonio Sitges-Serra
Journal:  Langenbecks Arch Surg       Date:  2009-06-25       Impact factor: 3.445

View more
  4 in total

1.  Use of Calcium and Parathyroid Hormone Nomogram to Distinguish Between Atypical Primary Hyperparathyroidism and Normal Patients.

Authors:  Olga A Lavryk; Allan E Siperstein
Journal:  World J Surg       Date:  2017-01       Impact factor: 3.352

2.  18F-Fluorocholine PET/CT as a second line nuclear imaging technique before surgery for primary hyperparathyroidism.

Authors:  Alessio Imperiale; David Taïeb; Elif Hindié
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-04       Impact factor: 9.236

3.  Reduced fracture incidence in patients having surgery for primary hyperparathyroidism.

Authors:  Martin Nilsson; Elin Ståhl; Kristina E Åkesson; Mark Thier; Erik Nordenström; Martin Almquist; Anders Bergenfelz
Journal:  Clin Endocrinol (Oxf)       Date:  2022-03-04       Impact factor: 3.523

4.  Added value of 18F-fluorocholine positron emission tomography-computed tomography in presurgical localization of hyperfunctioning parathyroid glands after dual tracer subtraction scintigraphy failure: A retrospective study of 47 patients.

Authors:  David Morland; Paul Lalire; Sophie Deguelte; Mohamad Zalzali; Capucine Richard; Sébastien Dejust; Camille Boulagnon; Sang Ly; Dimitri Papathanassiou; Brigitte Delemer
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.